New cancer treatments may be lying right under our noses – if we are willing to take a commercial risk.

We need to explore the chemical space outside of Lipinski’s rules.

Outsourcing partnerships aim to reduce costs and improve efficiencies, but don't overlook the human elements!

A half-century-old “bet hedging” hypothesis explains the effectiveness of many drug combinations.

Should we target minor rather than major infections with new therapeutics to best fight antibiotic resistance?

Who will be chosen for The Medicine Maker 2018 Power List? The power is in your hands.

London’s Science Museum highlights superbugs and the stars that fight against them in a new exhibition.

Some patients, particularly children, find medicines unpalatable – and genetics could be the cause.

The year 2018 will be one of yet more drug approvals, but which areas will be neglected?

Exploring the Future of Bioprocessing Together.